News

Deal Announcements

CoLucid Pharma Clears New Venture Capital Debt

Wednesday, June 29, 2011 5:31:00 AM PDT | VentureDeal Staff
Research triangle Park, North Carolina  --  CoLucid Pharmaceuticals has secured $1.5 million in new venture capital debt, according to an SEC regulatory filing.

CoLucid is developing therapies for central nervous system disorders such as migraine headaches.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

CoLucid is still seeking an additional $6 million, according to the filing.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1